Medical therapy of active Crohn's disease

Bailliere's Clinical Gastroenterology

Volumn 12, Issue 1, 1998, Pages 73-92

  Järnerot, Gunnar ^a,b   Sandberg Gertzén, Hanna ^b   Tysk, Curt ^a,b  

^a Department of Gastroenterology ^*

^b ÖREBRO MEDICAL CENTRE HOSPITAL   (Sweden)

Author keywords

Anti CD4 antibodies; Anti TNF antibodies; Corticosteroids; Crohn's disease; Immunosuppressives; Interferon; Interleukin 10; Salicylates

Indexed keywords

AZATHIOPRINE; CD4 ANTIGEN; CYCLOSPORIN; INTERFERON; INTERLEUKIN 10; MERCAPTOPURINE; METHOTREXATE; SALICYLIC ACID DERIVATIVE; STEROID; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ARTICLE; CROHN DISEASE; DOSE TIME EFFECT RELATION; HUMAN; IMMUNOMODULATION; PRIORITY JOURNAL; SIDE EFFECT; SYMPTOM;

EID: 0031844608     PISSN: 09503528     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0950-3528(98)90086-0     Document Type: Article

References (98)

1. Allan R & Cooke WT (1977) Evaluation of metronidazole in the management of Crohn's disease. Gut 18: 422. (Abstract).
2. Allison MC & Pounder RE (1984) Cyclosporine for Crohn's disease. Lancet 1: 902-903.
3. Ambrose NS, Allan RN, Keighley MRB et al (1985) Antibiotic therapy for treatment in relapse of intestinal Crohn's disease. Diseases of the Colon and Rectum 28: 81-85.
4. R) in Crohn's disease. A controlled double-blind study. Scandinavian Journal of Gastroenterology 9: 549-554.
5. Arora S, Katkov WN, Cooley J et al (1992) A double-blind, randomised, placebo-controlled trial of methotrexate in Crohn's disease. Gastroenterology 102: A591.
6. Baron TH, Truss CD & Elson CO (1993) Low-dose oral methotrexate in refractory inflammatory bowel disease. Digestive Diseases and Sciences 38: 1851-1856.
7. Basilisco G, Ranzi T, Campanini MC et al (1989) Controlled trial of rifabutin in Crohn's disease. Current Therapeutic Research 46: 245-250
8. Bauditz J, Haemling J, Ortner M et al (1997) Treatment with tumour necrosis factor inhibitor oxpentifylline does not improve corticosteroid dependent chronic active Crohn's disesase. Gut 40: 470-474.
9. Bernstein LH, Frank MS, Brandt LJ & Boley SJ (1980) Healing of perineal Crohn's disease with metronidazole. Gastroenterology 79: 357-365
10. Blickfeldt P, Blomhoff JP, Myhre E & Gjone E (1978) Metronidazole in Crohn's disease. A double blind cross-over clinical trial. Scandinavian Journal of Gastroenterology 13: 123-127.
11. Bouhnik Y, Lémann M, Mary JY et al (1996) Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet 347: 215-219.
12. *Brandt LJ, Bernstein LH, Boley SJ & Frank MS (1982) Metronidazole therapy for perineal Crohn's disease: A follow-up study. Gastroenterology 83: 383-387.
13. Brynskov J, Freund L, Rasmussen SN et al (1989) A placebo-controlled, double-blind, randomized trial of cyclosporine therapy in active Crohn's disease. New England Journal of Medicine 321: 845-850.
14. Brynskov J, Freund L, Rasmussen SN et al (1991) Final report on a placebo-controlled, double-blind, randomized multicentre trial of cyclosporine treatment in active Crohn's disease. Scandinavian Journal of Gastroenterology 26: 689-695.
15. Campieri M, Ferguson A, Doe W et al (1995) Oral budesonide competes favourably with prednisolone in active Crohn's disease. Gastroenterology 108: A790.
16. Candy S, Wright J, Gerber M et al (1995) A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 37: 674-678.
17. Canva-Delcambre V, Jacquot S, Robinet E et al (1996) Treatment of severe Crohn's disease with anti-CD4 monoclonal antibody. Alimentary Pharmacology and Therapeutics 10: 721-727.
18. Colombel JF, Mathieu D, Bonault JM et al (1995) Hyperbaric oxygenation in severe, perineal Crohn's disease. Diseases of the Colon and Rectum 38: 609-624.
19. Colombel JF, Lémann M, Cassagnou M et al (1996) Ciprofloxacin vs mesalazine in the treatment of active Crohn's disease. Gut 39 (supplement 3): A188. (Abstract).
20. Connell WR, Kamm MA, Lennard-Jones JE & Ritchie JK (1993) Bone marrow toxicity from azathioprine: twenty-seven year experience in inflammatory bowel disease. Gut 34: 1081-1085.
21. Connell WR, Kamm MA, Dickson M et al (1994) Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 343: 1249-1252.
22. th International Congress of Chemotherapy 1: 295-298.
23. Davidsen B, Munkholm P, Schlichting P et al (1995) Tolerability of Interferon alpha-2b, a possible new treatment of active Crohn's disease. Alimentary Pharmacology and Therapeutics 9: 75-79.
24. Deusch K, Mauthe B, Reiter C et al (1993) CD4-antibody treatment of inflammatory bowel disease: one-year follow up. Gastroenterology 104: A 691. (Abstract).
25. van Deventer SJH, Elson CO & Fedorak RN (1996a) Safety, tolerance, pharmacokinetics and pharmacodynamics of recombinant interleukin -10 (SCH 5 2000) in patients with steroid refractory Crohn's disease. Gastroenterology 110: A1034. (Abstract).
26. van Deventer SJH, Rutgeerts P, Targan SR et al (1996b) Anti-tumour necrosis factor antibody c A2 treatment induces clinical remissions in patients with active Crohn's disease. Gut 39 (supplement 3): A188. (Abstract).
27. van Dullemen HM, van Deventer SJH, Hommes DH et al (1995) Treatment of Crohn's disease with anti-tumour necrosis factor chimeric monoclonal antibody (c A2) Gastroenterology 109: 129-135.
28. Dupas JL, Brazier F, Yzet T et al (1996) Use of heparin in the treatment of chronically active Crohn's disease. Gut 39 (supplement 3): A166. (Abstract).
29. Elliot PR, Burnham WR, Berghouse LM et al (1982) Sulphadoxine-pyrimethamine therapy in Crohn's disease. Digestion 23: 132-134.
30. Ewe K, Press AG, Singe CC et al (1993) Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease. Gastroenterology 105: 367-372.
31. Feagan BG, McDonald JWD, Rochon J et al (1994) Low-dose cyclosporine for the treatment of Crohn's disease. New England Journal of Medicine 330: 1846-1851.
32. Feagan BG, Rochon J, Fedorak RN et al (1995) Methotrexate for the treatment of Crohn's disease. New England Journal of Medicine 332: 292-297.
33. Gasché C, Reinisch W, Vogelsang H et al (1995) Prospective evaluation of interferon-α in treatment of chronic active Crohn's disease. Digestive Diseases and Sciences 40: 800-804.
34. Greenberg GR, Feagan BG, Martin F et al (1994) Oral budesonide for active Crohn's disease. New England Journal of Medicine 331: 836-841.
35. Greenberg GR, Feagan BG, Martin F et al (1996) Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled, dose-ranging study. Gastroenterology 110: 45-51.
36. Gross V, Andus T, Fischbach W et al (1995) Comparison between high dose 5-aminosalicylic acid and 6-methylprednisolone in active Crohn's ileocolitis. A multicenter randomized double-blind study. German 5-ASA study group. Zeitschrift für Gastroenterologie 33: 581-584.
37. D'Haens G, Vandeputte L, Baert F & Rutgeerts P (1997) Methotrexate is effective to treat refractory Crohn's disease. Gastroenterology 112: A959.
38. D'Haens G, Verstaete A, Baert F et al (1996) Osteoblast function is suppressed by oral methylprednisolone but not by budesonide CIR in active ileocolonic Crohn's disease. Gastroenterology 110: A894.
39. Hampson SJ, Parker MC, Saverymuttu SH et al (1989) Quadruple antimycobacterial chemotherapy in Crohn's disease: results at 9 months of a pilot study in 20 patients. Alimentary Pharmacology and Therapeutics 3: 343-352.
40. Hanauer SB & Smith MB (1993) Rapid closure of Crohn's disease fistulas with continuous intravenous cyclosporin A. American Journal of Gastroenterology 88: 646-649.
41. Hellers G, Löfberg R, Rutgeerts P et al (1996) Oral budesonide for prevention of recurrence following ileocecal resection of Crohn's disease. A one-year placebo-controlled study. Gastroenterology 110: A923.
42. Jewell DP, Lennard-Jones JE and the Cyclosporine study Group of Great Britain and Ireland (1994) Oral Cyclosporine for chronic active Crohn's disease: a multicentre controlled trial. European Journal of Gastroenterology and Hepatology 6: 499-505.
43. Klein M, Binder HJ, Mitchell M et al (1974) Treatment of Crohn's disease with azathioprine: a controlled evaluation. Gastroenterology 66: 916-922.
44. Korelitz BI & Present DH (1985) Favorable effect of 6-mercaptopurine on fistulae of Crohn's disease. Digestive Diseases and Sciences 30: 58-64.
45. Kozarek RA (1993) Review article: immunosuppressive therapy for inflammatory bowel disease. Alimentary Pharmacology and Therapeutics 7: 117-123.
46. Kozarek RA, Patterson DJ, Gelfand MD et al (1989) Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Annals of Internal Medicine 110: 353-356.
47. Kozarek RA, Patterson DJ, Botoman VA et al (1991) Methotrexate use in inflammatory bowel disease patients who have failed azathioprine or 6-mercaptopurine. Gastroenterology 100: A222.
48. Krook A, Danielsson D, Kjellander J & Järnerot G (1981a) The effect of metronidazole and sulphasalazine on the faecal flora in patients with Crohn's disease. Scandinavian Journal of Gastroenterology 16: 183-192.
49. Krook A, Lindström B, Kjellander J et al (1981b) Relation between concentrations of metronidazole and Bacteroides species in faeces of patients with Crohn's disease and healthy individuals. Journal of Clinical Pathology 34: 645-650.
50. Langholz E, Brynskov J, Bendtzen K et al (1992) Treatment of Crohn's disease with fusidic acid: an antibiotic with immunosuppressive properties similar to cyclosporine. Alimentary Pharmacology and Therapeutics 6: 495-502.
51. Lavy A, Weisz G, Adir Y et al (1994) Hyperbaric oxygen for perianal Crohn's disease. Journal of Clinical Gastroenterology 19: 202-205.
52. Lémann M, Chamiot-Prieur C, Mesnard B et al (1996) Methotrexate for the treatment of refractory Crohn's disease. Alimentary Pharmacology and Therapeutics 10: 309-314.
53. Levine DS, Fischer SH, Christie DL et al (1992) Intravenous immunoglobulin therapy for active, extensive and medically refractory idiopathic ulcerative or Crohn's colitis. American Journal of Gastroenterology 87: 91-100.
54. Löfberg R (1995) New steroids for inflammatory bowel disease. Inflammatory Bowel Diseases 1: 135-141.
55. Löfberg R, Rutgeerts P, Malchow H et al (1996) Budesonide prolongs time to relapse in ileal and ileocecal Crohn's disease. A placebo controlled one year study. Gut 39: 82-86.
56. Mahadevan V, Marion JF & Present DH (1997) The place for methotrexate in the treatment of refractory Crohn's disease. Gastroenterology 112: A1031. (Abstract).
57. Mahida YR & Jewell DP (1990) Slow-release 5-aminosalicylic acid (Pentasa) for the treatment of active Crohn's disease. Digestion 45: 88-92.
58. Malchow H, Ewe K, Brandes JW et al (1984) European Cooperative Crohn's disease study (ECCDS): results of drug treatment. Gastroenterology 86: 249-266.
59. Markowitz J, Rosa J, Grancher K et al (1990) Long-term 6-mercaptopurine treatment in adolescents with Crohn's disease. Gastroenterology 99: 1347-1351.
60. Morgan SL, Baggott JE, Vaughn WH et al (1990) The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis and Rheumatism 33: 9-18.
61. Moss AA, Carbone JV & Kressel H. (1977) Crohn's disease responds to antibiotics. Journal of the American Medical Association 237: 629.
62. Munkholm P, Langholz E, Davidsen M & Binder V (1994) Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 35: 360-362.
63. O'Brien JJ, Bayless TM & Bayless JA (1991) Use of azathioprine or 6-mercaptopurine in the treatment of Crohn's disease. Gastroenterology 101: 39-46.
64. Pearson DC, May GR, Fick GH & Sutherland LR (1995) Azathioprine and 6-mercaptopurine in Crohn's disease. A meta-analysis. Annals of Internal Medicine 123: 132-142.
65. Prantera C, Kohn A, Mangiarotti R et al (1994) Antimycobacterial therapy in Crohn's disease: results of a controlled, double-blind trial with a multiple antibiotic regimen. American Journal of Gastroenterology 89: 513-518.
66. Prantera C, Zannoni F, Scribano ML et al (1996) An antibiotic regimen for the treatment of active Crohn's disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin. American Journal of Gastroenterology 91: 328-332.
67. Present DH & Lichtiger S (1994) Efficacy of cyclosporine in treatment of fistula of Crohn's disease. Digestive Diseases and Sciences 39: 374-380.
68. Present DH, Korelitz BI, Wisch N et al (1980) Treatment of Crohn's disease with 6-mercaptopurine. New England Journal of Medicine 303: 981-987.
69. R. Scandinavian Journal of Gastroenterology 22: 877-883.
70. Reynolds JC, Trellis DR, Abu-Elmagd K & Fung J (1993) The rationale for FK 506 in inflammatory bowel disease. Canadian Journal of Gastroenterology 7: 208-210.
71. Rhodes J, Beck P, Bainton D & Campbell H (1971) Controlled trial of azathioprine in Crohn's disease. Lancet 2: 1273-1276.
72. Rijk MC, van Hogezand RA, van Lier HJJ & van Tongren JH (1991) Sulphasalazine and prednisone compared with sulphasalazine for treating active Crohn's disease. Annals of Internal Medicine 114: 445-450.
73. Rutgeerts P, Geboes K, Vantrappen G et al (1992) Rifabutin and ethambutol do not help recurrent Crohn's disease in the neoterminal ileum. Journal of Clinical Gastroenterology 15: 24-28.
74. Rutgeerts P, Löfberg R, Malchow H et al (1994) A comparison of budesonide with prednisolone for active Crohn's disease. New England Journal of Medicine 331: 842-845.
75. Rutgeerts P, Hiele M, Geboes K et al (1995) Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology 108: 1617-1621.
76. Rutgeerts P, D'Haens G, van Deventer SJH et al (1997) Retreatment with anti-TNF-α chimeric antibody (c A2) effectively maintains c A2-induced remission in Crohn's disease. Gastroenterology 112: A1078. (Abstract).
77. Sandborn WJ (1995) A critical review of cyclosporine therapy in inflammatory bowel disease. Inflammatory Bowel Disease 1: 48-63.
78. Sandbom WJ (1997) A preliminary report on the use of oral tacrolimus (FK506) in the treatment of complicated proximal small bowel and fistulizing Crohn's disease. Gastroenterology 112: A1080.
79. Sandborn WJ, Tremaine WJ & Lawson GM (1996) Clinical response does not correlate with intestinal or blood cyclosporine concentrations in patients with Crohn's disease treated with high-dose oral cyclosporine. American Journal of Gastroenterology 91: 37-43.
80. Sandborn WJ, van Os EC, Zins BJ et al (1995) An intravenous loading dose of azathioprine decreases the time to response in patients with Crohn's disease. Gastroenterology 109: 1808-1817.
81. Schmidt Ch (1996) Therapy of refractory Crohn's disease by 7 S-immunoglobulins. Gut 39 (supplement 3): A166. (Abstract).
82. Scholmerich J, Jenss H, Hartmann F & Dopfer H (1990) Oral 5-aminosalicylic acid versus 6-methylprednisolone in active Crohn's disease. Canadian Journal of Gastroenterology 4: 446-451.
83. Singleton JW, Hanauer SB & Robinson M (1995) Quality-of-life results of double-blind, placebo-controlled trial of mesalamine in patients with Crohn's disease. Digestive Diseases and Sciences 40:931-935.
84. Singleton JW, Hanauer SB, Gitnick GL et al (1993) Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Gastroenterology 104: 1293-1301.
85. Solomon MJ, McLeod RS, O'Connor BI et al (1993) Combination ciprofloxacin and metronidazole in severe perianal Crohn's disease. Canadian Journal of Gastroenterology 7: 571-574.
86. Stack WA, Mann SD, Roy AJ et al (1997) Randomized controlled trial of CDP 571 antibody to tumour necrosis factor-α in Crohn's disease. Lancet 349: 521-524.
87. Ståhlberg D, Bárány F, Einarsson K et al (1991) Neurophysiologic studies of patients with Crohn's disease on long-term treatment with metronidazole. Scandinavian Journal of Gastroenterology 26:219-224.
88. Stange EF, Modigliani R, Pena AS et al (1995) European trial of cyclosporine in chronic active Crohn's disease: a 12-month study. Gastroenterology 109: 774-782.
89. 'Summers RW, Switz DM, Sessions JT et al (1979) National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology 77: 847-869.
90. Sutherland L, Singleton J, Sessions J et al (1991) Double blind, placebo controlled trial of metronidazole in Crohn's disease. Gut 32: 1071-1075.
91. Swift GL, Srivastava ED, Stone R et al (1994) Controlled trial of anti-tuberculous chemotherapy for two years in Crohn's disease. Gut 35: 363-368.
92. Thomsen OO, Cortot A, Jewell DP et al (1997) Budesonide CIR is more effective than mesalazine in active Crohn's disease. A 16 week, international randomized, double-blind multicentre trial. Gastroenterology 112: A1104.
93. Tremaine WJ, Schroeder KW, Harrison JM & Zinsmeister AR (1994) A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn's colitis and ileocolitis. Journal of Clinical Gastroenterology 19: 278-282.
94. Turunen U, Färkkilä, Valtonen V & Seppälä K (1993) Long-term outcome of ciprofloxacin treatment in severe perianal or fistulous Crohn's disease. Gastroenterology 104: A793. (Abstract).
95. Ursing B & Kamme C (1975) Metronidazole for Crohn's disease. Lancet 1: 775-777.
96. 'Ursing B, Alm T, Bárány F et al (1982) A comparative study of metronidazole and sulfasalazine for active Crohn's disease: The Cooperative Crohn's Disease Study in Sweden. II Result. Gastroenterology 83: 550-562.
97. Willoughby JMT, Beckett J, Kumar P & Dawson AM (1971) Controlled trial of azathioprine in Crohn's disease. Lancet 2: 944-947.
98. Wright JP, Jewell DP, Modigliani R & Malchow H (1995) A randomized, double-blind, placebo-controlled trial of olsalazine for active Crohn's disease. Inflammatory Bowel Diseases 1: 241-246.